The UK medicines regulator has updated its official safety guidance for Mounjaro, Ozempic and similar weight loss jabs, flagging a rare but potentially fatal risk of severe pancreatitis. If you are currently taking one of these treatments privately, here is exactly what the new warning means for you. This is not a reason to panic — but it is a reason to read carefully.
In January 2026, the Medicines and Healthcare products Regulatory Agency — the MHRA, which is the UK equivalent of a medicines safety watchdog — updated its official product information for all GLP-1 and dual GLP-1/GIP weight loss injections. That includes semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro [GOV.UK (MHRA), 29 January 2026].
The update specifically highlights a small but serious risk of severe acute pancreatitis. Pancreatitis means dangerous inflammation of the pancreas, the organ that sits behind your stomach and helps you digest food [GOV.UK (MHRA), 29 January 2026].
The MHRA pancreatitis warning goes further than previous guidance. It now mentions rare reports of necrotising pancreatitis — where pancreatic tissue actually dies — and fatal cases [GOV.UK (MHRA), 29 January 2026]. These cases are rare. But the regulator felt the risk was serious enough to update labelling across the entire class of medicines.
Why is the MHRA flagging this now?
GLP-1 medicines have been linked to pancreatitis since they were first introduced. The connection has been debated in medical literature for years. What is new here is the explicit acknowledgement of necrotising and fatal cases, and the formal instruction to doctors [GOV.UK (MHRA), 29 January 2026].
The updated guidance specifically urges clinicians — that means your GP, your pharmacist, and any private prescriber — to ask patients directly whether they are taking a privately prescribed GLP-1 treatment [GOV.UK (MHRA), 29 January 2026].
This matters because hundreds of thousands of UK women are now getting Mounjaro or Ozempic through private online clinics. Those prescriptions do not automatically appear on NHS records [GOV.UK (MHRA), 29 January 2026]. If you are admitted to hospital with stomach pain and your doctor does not know you are on tirzepatide or semaglutide, they cannot make a safe diagnosis quickly.
What are the warning signs of pancreatitis?
The MHRA guidance instructs prescribers to stop treatment immediately if pancreatitis is suspected [GOV.UK (MHRA), 29 January 2026]. So it is worth knowing what to look for.
The classic symptoms of acute pancreatitis include severe pain in the upper abdomen or back, nausea, vomiting, and a fever. The pain often comes on suddenly and can be intense. It frequently gets worse after eating [NHS, 2024].
These symptoms can overlap with common GLP-1 side effects like nausea and stomach discomfort. That is precisely why the warning matters. If your stomach symptoms are severe, persistent, or accompanied by back pain, do not assume it is ordinary nausea. Seek medical attention straight away.
If you go to A&E or call 111, tell the clinician you are taking a GLP-1 weight loss injection. Mention the exact medicine and the dose. Do not wait to be asked.
How common is this risk in real numbers?
To be clear: pancreatitis is not a common side effect of these medicines. Clinical trial data for tirzepatide showed pancreatitis occurring in less than 1% of participants [New England Journal of Medicine, SURMOUNT-1, 2022]. The MHRA update does not suggest the risk has suddenly increased. It means the regulator wants the most serious possible outcomes — including death — to be clearly documented and communicated [GOV.UK (MHRA), 29 January 2026].
For context, pancreatitis can also be triggered by gallstones and heavy alcohol use. It is not unique to GLP-1 medicines. But if you are taking one of these injections, the MHRA pancreatitis warning means you now have one more reason to be aware of the symptoms.
Who is at higher risk?
The updated MHRA guidance does not specify a single high-risk profile. However, previous research has suggested that people with a personal or family history of pancreatitis, gallstones, or very high triglyceride levels — a type of fat in the blood — may face a higher baseline risk [NHS, 2024].
If any of those apply to you, it is worth raising the MHRA pancreatitis warning explicitly with your prescriber before your next dose. A good private clinic will already be asking these questions at the assessment stage. If yours did not, that is worth noting.
What should you actually do right now?
You do not need to stop your treatment based on this update alone. The MHRA has not suspended or restricted prescribing of these medicines. The update is about informed awareness, not prohibition [GOV.UK (MHRA), 29 January 2026].
Here is a practical checklist based on the updated guidance.
Tell every clinician you see. That includes your NHS GP, any A&E doctor, your dentist before sedation, and any specialist you are referred to. Tell them you are taking a GLP-1 injection, which one, and at what dose.
Know the symptoms. Severe upper abdominal or back pain, especially with vomiting, is a medical emergency. Do not manage it at home. Call 999 or go to A&E.
Check your clinic’s follow-up process. A responsible private prescriber should be monitoring you and asking about any new symptoms at each check-in. If yours is not, ask why.
Do not skip your prescription review. The MHRA update reinforces why regular clinical oversight matters. The convenience of a quick online subscription does not outweigh the need for a real prescriber relationship.
The bigger picture
The MHRA pancreatitis warning is part of a broader pattern of the regulator tightening its oversight of the GLP-1 medicine class as use grows rapidly across the UK. These are powerful medicines with real benefits. They are also medicines that require proper medical supervision.
The fact that rare but fatal outcomes are now explicitly documented in the product information is not a scandal. It is how drug safety is supposed to work. Regulators collect reports, update labelling, and keep clinicians informed [GOV.UK (MHRA), 29 January 2026].
What it does mean is that the era of treating Mounjaro or Ozempic like a routine supplement is over. These are prescription medicines with a real safety profile. The MHRA pancreatitis warning deserves to be read, understood, and acted on — not scrolled past.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
